A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Breast Cancer Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00036621
• Other study ID #: CA161-006
• Status: Terminated
• Phase: Phase 2
• First received: May 11, 2002
• Last updated: February 27, 2010

Study information

• Verified date: August 2007
• Source: Bristol-Myers Squibb
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This clinical trial will assess whether BMS-275291 can be administered safely in combination with standard adjuvant therapy for early breast cancer and whether plasma concentrations at trough exceed a target minimum.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. primary completion date: September 2002
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed pathologic stage 1c-IIIA adenocarcinoma of the breast which has been completely resected.

2. Systemic therapy is planned according to one of the following three regimens:

• Tamoxifen (20mg) given orally once per day

• Adriamycin (60 mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery)

• Adriamycin (60mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1), repeated every 21 days for four courses, followed by Taxol (175mg/m2 IV on Day 85) repeated every 21 days for four courses (to begin within 8 weeks after definitive surgery).

3. ECOG performance status 0 or 1.

4. Adequate organ function as evidenced by:

• ANC > 1500/mm3

• Platelets > 100,000/mm3

• Serum Creatine < 1.5 ULN

• Total bilirubin < 1.5 x ULN

• AST < 2 x ULN

5. Patients to receive adriamycin must have LVEF > 50% or acceptable function per the institutional practice as assessed by MUGA.

6. Signed informed consent.

7. Women age =/> 18 years

8. Patients must have recovered from reversible adverse events of prior surgery and any radiation therapy.

9. Women of childbearing potential must have a serum or urine pregnancy test within 72 hours prior to the start of study medication.

Exclusion Criteria:

1. Patients in whom breast cancer is present at the margin or surgical resection are not eligible in this study. Patients suspicious for residual disease following resection are not eligible.

2. Prior chemotherapy or immunotherapy for breast cancer.

3. Documented metastatic breast cancer.

4. Other malignancy (except carcinoma in situ of the cervix or surgically treated non-melanoma skin cancer) within 5 years of study entry.

5. Pregnant or breastfeeding females.

6. Women of child bearing potential not employing adequate contraception.

7. History of autoimmune diseases such as systemic lupus, rheumatoid arthritis, scleroderma.

8. Any serious underlying medical conditions which would impair the ability ot the patient to receive the planned treatment or which may interfere with the completion of this trial.

9. Planned chemotherapy, hormonal therapy or biological therapy other than those described above. Patients should not be enrolled in any other clinical trials. Use of other investigational agents is not permitted.

10. Any condition that does not permit compliance with the protocol.

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Drug:
• BMS-275291

Locations

Country	Name	City	State
United States	Local Institution	Baltimore	Maryland
United States	Local Institution	Bronx	New York
United States	Local Institution	Burlington	Vermont
United States	Local Institution	Chicago	Illinois
United States	Local Institution	Cincinnati	Ohio
United States	Local Institution	Green Bay	Wisconsin
United States	Local Institution	Indianapolis	Indiana
United States	Local Institution	Portland	Oregon
United States	Local Institution	Vancouver	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

External Links

•   BMS Clinical Trials Disclosure
•   For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm